Pharmacy

Your Article Summary

See Latest Articles

Update on the use of deferasirox in the management of iron overload
Therapeutics and Clinical Risk Management, 11/04/09

Taher A et al. – Based on a comprehensive clinical development program, the once–daily, oral iron chelator deferasirox (Exjade) is approved for the treatment of transfusional iron overload in adult and pediatric patients with various transfusion–dependent anemias, including beta–thalassemia and the myelodysplastic syndromes. Deferasirox dose should be titrated for each individual patient based on transfusional iron intake, current iron burden and whether the goal is to decrease or maintain body iron levels. Doses of >30 mg/kg/day have been shown to be effective with a safety profile consistent with that observed at doses <30 mg/kg/day. Recent data have highlighted the ability of deferasirox to decrease cardiac iron levels and to prevent the accumulation of iron in the heart. The long–term efficacy and safety of deferasirox for up to 5 years of treatment have now been established. The availability of this effective and generally well tolerated oral therapy represents a significant advance in the management of transfusional iron overload.

Today in Other Drugs...keeping you current

Receive free subspecialty "5-minute updates" via email

Persistence with injectable antidiabetic agents in members with type 2 diabetes in a commercial managed care organization
Current Medical Research and Opinion, 11/25/09

Anti-relapse medications: Preclinical models for drug addiction treatment
Pharmacology & Therapeutics, 11/25/09

Glibenclamide-related excess in total and cardiovascular mortality risks: Data from large Ukrainian observational cohort study
Diabetes Research and Clinical Practice, 11/25/09

 See all of Other Drugs